Microbot Medical Inc.

Microbot Medical Inc. is a medical device company dedicated to the research, design, and development of next-generation robotic endoluminal surgery devices. Headquartered in Hingham, Massachusetts, the company's mission is to deliver transformative interventional robotic solutions that prioritize patient care, empower providers, and enable access to advanced care anytime, anywhere.

The company's flagship product is the LIBERTY® Endovascular Robotic Surgical System, a fully disposable, single-use, and remotely operated robotic solution designed for various endovascular interventional procedures, including those in peripheral vascular, and potentially neurovascular spaces. The LIBERTY system aims to enhance precision, reduce radiation exposure for medical professionals, and broaden access to advanced care by offering a compact and cost-effective alternative to traditional capital equipment. Microbot Medical also holds intellectual property related to other micro-robotic technologies such as ViRob, TipCAT, CardioSert, and NovaCross.

Led by Chairman, President, and CEO Harel Gadot, Microbot Medical achieved a significant milestone with FDA 510(k) clearance for its LIBERTY® system in September 2025. Following this, the company initiated a limited market release in late 2025 and commenced a full market release in the U.S. in April 2026. Notable collaborations include partnerships with Corewell Health and Emory University for the development of the LIBERTY system and autonomous robotics, with Emory Healthcare successfully completing initial robotic peripheral endovascular procedures using LIBERTY in March 2026. The company maintains a robust intellectual property portfolio, with 42 issued patents and 23 pending applications worldwide.